QQ客服 官方微博 反馈留言

	冠心病PCI手术患者抑酸药物的选用分析; Analysis of acid-suppressive drug choice after PCI in patients with coronary heart diseases
	杜瑜 ; 王淼 ; 潘金水
	2013-04-30
关键词	冠心病 经皮冠脉支架植入术 抑酸药物 质子泵抑制剂 上消化道出血 合理用药 coronary heart disease percutaneous coronary interventions acid-suppressive drugs proton pump inhibitors upper gastrointestinal bleeding reasonable drug use
英文摘要	目的:通过对中山医院(以下简称我院)冠心病经皮冠状动脉支架手术(PErCuTAnEOuS COrOnAry InTErVEnTIOnS,PCI)患者应用抑酸药物的情况进行分析,为临床合理用药提供参考。方法:抽查我院179例进行了PCI手术患者的病例,统计其抑酸药物的使用品种、给药方案、药物更换及合并用药等。结果:调查病例中有87.71%的患者应用了抑酸药物预防上消化道出血(uPPEr gASTEOInTESTInAl,ugI),平均使用天数为(10.39±8.59)d;主要选择的抑酸药物为雷贝拉唑、泮托拉唑和法莫替丁;联合使用药物最多的是铝碳酸镁。结论:对于接受双联抗血小板治疗的PCI手术患者,目前尚缺乏指南来指导其科学地预防ugI,因此需要更进一步的临床研究来保障其用药安全,促进抑酸药物在该类患者中的合理应用。; Objective: To analyze the acid-suppressive drug use after percutaneous coronary interventions(PCI) in patients with coronary heart diseases in Zhongshan Hospital,so as to provide references for their rational use.Methods: Totally 179 medical records of the patients having received PCI were reviewed.Their varieties,dosing regimens,drug replacement and concomitant medications of acid-suppressive drugs were surveyed.Results: Acid-suppressive drugs were used in 87.71% patients during the treatment,and the average use duration of each patient was(10.39±8.59) d.Rabeprazole,pantoprazole and famotidine were the most used acid-suppressive drugs.Hydrotalcite was the most used drug in combination with other drugs.Conclusion: There is no guidelines for the scientific prevention of UGI in patients receiving double antiplatelet therapy after PCI,therefore,the further clinical research is necessary to ensure the safe and rational use of acid-suppressive drugs.
语种	zh_CN
内容类型	期刊论文
源URL	[http://dspace.xmu.edu.cn/handle/2288/123413]
专题	药学院－已发表论文
推荐引用方式 GB/T 7714	杜瑜,王淼,潘金水. 冠心病PCI手术患者抑酸药物的选用分析, Analysis of acid-suppressive drug choice after PCI in patients with coronary heart diseases[J],2013.
APA	杜瑜,王淼,&潘金水.(2013).冠心病PCI手术患者抑酸药物的选用分析..
MLA	杜瑜,et al."冠心病PCI手术患者抑酸药物的选用分析".(2013).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。